Idiopathic Pulmonary Fibrosis Treatment Market Report | Size, Share & Growth Outlook 2030

<h2 class='h5'>Idiopathic Pulmonary Fibrosis Treatment Market Report Scope</h2><div class='gt-ig-table mt-4 row'><div class='col-12 col-lg-8 mx-auto text-lg-start'><table class='shadow table table-bordered table-striped'><tr><th>Report Attribute<th>Details<tr><td>Market size in 2022<td>US$ 4,360.87 Million <tr><td>Market Size by 2030<td>US$ 10,784.07 Million <tr><td>Global CAGR (2022 - 2030)<td>12.0%<tr><td>Historical Data<td>2020-2022<tr><td>Forecast period<td>2022-2030<tr><td>Segments Covered<td><span>By Drug Type </span><ul><li>Nintedanib</li><li> Pirfenidone</li></ul><span>By Distribution Channel </span><ul><li>Hospital Pharmacies</li><li> Retail Pharmacies and Online Pharmacies</li></ul></tr><tr><td>Regions and Countries Covered<td><span>North America </span><ul><li>US</li><li> Canada</li><li> Mexico </li></ul><span>Europe </span><ul><li>UK</li><li> Germany</li><li> France</li><li> Russia</li><li> Italy</li><li> Rest of Europe </li></ul><span>Asia-Pacific </span><ul><li>China</li><li> India</li><li> Japan</li><li> Australia</li><li> Rest of Asia-Pacific </li></ul><span>South and Central America </span><ul><li>Brazil</li><li> Argentina</li><li> Rest of South and Central America </li></ul><span>Middle East and Africa </span><ul><li>South Africa</li><li> Saudi Arabia</li><li> UAE</li><li> Rest of Middle East and Africa</li></ul></tr><tr><td>Market leaders and key company profiles<td><li></li><li> C.H. Boehringer Ingelheim International GmbH </li><li> Bristol-Myers Squibb Company </li><li> F. Hoffmann-La Roche Ltd </li><li> AstraZeneca </li><li> Shionogi and Co. Ltd. </li><li> Cipla Ltd </li><li> Others </li><li></li></tr></table></div></div>

<h2 class='h5'>特发性肺纤维化治疗市场报告范围</h2><div class='gt-ig-table mt-4 row'><div class='col-12 col-lg-8 mx-auto text-lg-start'><table class='shadow table table-bordered table-striped'><tr><th>报告属性<th>详细信息<tr><td>2022年市场规模<td>43.6087亿美元 <tr><td>2030年市场规模<td>107.8407亿美元 <tr><td>全球复合年增长率（2022-2030）<td>12.0%<tr><td>历史数据<td>2020-2022 <tr><td>预测期<td>2022-2030 <tr><td>涵盖的细分市场<td><span>按药物类型 </span><ul><li>尼达尼布</li><li>吡非尼酮</li></ul><span>按分销渠道 </span><ul><li>医院药房</li><li>零售药房及在线药房</li></ul></tr><tr><td>涵盖的地区和国家<td><span>北美 </span><ul><li>美国</li><li>加拿大</li><li>墨西哥</li></ul><span>欧洲 </span><ul><li>英国</li><li>德国</li><li>法国</li><li>俄罗斯</li><li>意大利</li><li>欧洲其他地区</li></ul><span>亚太地区 </span><ul><li>中国</li><li>印度</li><li>日本</li><li>澳大利亚</li><li>亚太其他地区</li></ul><span>南美和中美洲 </span><ul><li>巴西</li><li>阿根廷</li><li>南美和中美洲其他地区</li></ul><span>中东和非洲 </span><ul><li>南非</li><li>沙特阿拉伯</li><li>阿联酋</li><li>中东和非洲其他地区</li></ul></tr><tr><td>市场领先企业和关键公司简介<td><li></li><li> C.H. Boehringer Ingelheim International GmbH </li><li> Bristol-Myers Squibb Company </li><li> F. Hoffmann-La Roche Ltd </li><li> AstraZeneca </li><li> Shionogi and Co. Ltd. </li><li> Cipla Ltd </li><li> 其他</li><li></li></tr></table></div></div>